002294 信立泰
已收盘 12-05 15:00:00
资讯
新帖
简况
信立泰最新公告：SAL0140片获得临床试验批准通知书
证券之星 · 12-03
信立泰最新公告：SAL0140片获得临床试验批准通知书
11月26日信立泰涨5.69%，中欧医疗健康混合A基金重仓该股
证券之星 · 11-26
11月26日信立泰涨5.69%，中欧医疗健康混合A基金重仓该股
信立泰（002294）披露SAL0139获得临床试验批准通知书，11月21日股价下跌1.59%
证券之星 · 11-21
信立泰（002294）披露SAL0139获得临床试验批准通知书，11月21日股价下跌1.59%
信立泰(002294.SZ)：创新小分子药物SAL0139获批开展治疗高脂血症临床试验
智通财经 · 11-21
信立泰(002294.SZ)：创新小分子药物SAL0139获批开展治疗高脂血症临床试验
信立泰（002294）披露将参加深圳辖区上市公司投资者网上集体接待日活动，11月14日股价下跌0.45%
证券之星 · 11-14
信立泰（002294）披露将参加深圳辖区上市公司投资者网上集体接待日活动，11月14日股价下跌0.45%
11月13日信立泰涨5.40%，中欧医疗健康混合A基金重仓该股
证券之星 · 11-13
11月13日信立泰涨5.40%，中欧医疗健康混合A基金重仓该股
信立泰（002294）披露股东减持股份预披露公告，11月10日股价上涨2.21%
中金财经 · 11-10
信立泰（002294）披露股东减持股份预披露公告，11月10日股价上涨2.21%
信立泰最新公告：股东润复拟减持不超0.07%股份
证券之星 · 11-10
信立泰最新公告：股东润复拟减持不超0.07%股份
信立泰（002294）2025年三季报简析：营收净利润同比双双增长，应收账款上升
证券之星 · 10-29
信立泰（002294）2025年三季报简析：营收净利润同比双双增长，应收账款上升
信立泰(002294)9月30日股东户数2.52万户，较上期增加4.87%
证券之星 · 10-28
信立泰(002294)9月30日股东户数2.52万户，较上期增加4.87%
信立泰最新公告：前三季净利润5.81亿元同比增长13.93%
证券之星 · 10-27
信立泰最新公告：前三季净利润5.81亿元同比增长13.93%
信立泰（002294）披露JK06境外临床试验进展，10月20日股价下跌1.71%
证券之星 · 10-20
信立泰（002294）披露JK06境外临床试验进展，10月20日股价下跌1.71%
信立泰(002294.SZ)SAL0137药品临床试验申请获受理
智通财经 · 10-15
信立泰(002294.SZ)SAL0137药品临床试验申请获受理
信立泰最新公告：JK07、JK06境外临床试验取得阶段性进展
证券之星 · 09-29
信立泰最新公告：JK07、JK06境外临床试验取得阶段性进展
信立泰(002294.SZ)：SAL0140药品临床试验申请获得受理
智通财经 · 09-29
信立泰(002294.SZ)：SAL0140药品临床试验申请获得受理
9月23日信立泰涨5.55%，中欧医疗健康混合A基金重仓该股
证券之星 · 09-23
9月23日信立泰涨5.55%，中欧医疗健康混合A基金重仓该股
研报掘金丨天风证券：维持信立泰“买入”评级，多条管线有望迎来收获期
格隆汇 · 09-15
研报掘金丨天风证券：维持信立泰“买入”评级，多条管线有望迎来收获期
信立泰(002294.SZ)：SAL0139药品临床试验申请获受理
智通财经 · 09-05
信立泰(002294.SZ)：SAL0139药品临床试验申请获受理
信立泰最新公告：恩那罗®新增适应症获批 用于治疗透析慢性肾脏病患者贫血
证券之星 · 09-05
信立泰最新公告：恩那罗®新增适应症获批 用于治疗透析慢性肾脏病患者贫血
信立泰(002294.SZ)：自研创新小分子药物SAL0140片临床试验申请获得受理
智通财经 · 08-28
信立泰(002294.SZ)：自研创新小分子药物SAL0140片临床试验申请获得受理
加载更多
公司概况
公司名称：
深圳信立泰药业股份有限公司
所属行业：
医药制造业
上市日期：
2009-09-10
主营业务：
深圳信立泰药业股份有限公司的主营业务是药品、医疗器械产品的研发、生产、销售，以及专利授权许可。公司的主要产品是心血管类药物及医疗器械、头孢类抗生素及原料、骨科药物。
发行价格：
41.98
{"stockData":{"symbol":"002294","market":"SZ","secType":"STK","nameCN":"信立泰","latestPrice":60.5,"timestamp":1764918189000,"preClose":61.81,"halted":0,"volume":3455754,"delay":0,"changeRate":-0.0212,"floatShares":1115000000,"shares":1115000000,"eps":0.6033,"marketStatus":"已收盘","change":-1.31,"latestTime":"12-05 15:00:00","open":61.88,"high":61.88,"low":59.8,"amount":209000000,"amplitude":0.0337,"askPrice":60.51,"askSize":29,"bidPrice":60.5,"bidSize":3,"shortable":0,"etf":0,"ttmEps":0.6033,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765157400000},"marketStatusCode":5,"adr":0,"adjPreClose":61.81,"symbolType":"stock","openAndCloseTimeList":[[1764898200000,1764905400000],[1764910800000,1764918000000]],"highLimit":67.99,"lowLimit":55.63,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1114816535,"isCdr":false,"pbRate":7.85,"roa":"--","peRate":100.281784,"roe":"6.67%","epsLYR":0.54,"committee":-0.108108,"marketValue":67446000000,"turnoverRate":0.0031,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2025-12-08。","floatMarketCap":67431000000},"requestUrl":"/m/hq/s/002294","defaultTab":"news","newsList":[{"id":"2588175560","title":"信立泰最新公告：SAL0140片获得临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2588175560","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588175560?lang=zh_cn&edition=full","pubTime":"2025-12-03 18:10","pubTimestamp":1764756623,"startTime":"0","endTime":"0","summary":"信立泰(002294.SZ)公告称，公司近日收到国家药品监督管理局核准签发的《临床试验批准通知书》，同意公司自主研发的创新小分子药物SAL0140片开展治疗慢性肾脏病（CKD）的临床试验。SAL0140是公司具有自主知识产权的醛固酮合酶抑制剂，若能研发成功并获批上市，将有望为更多细分领域的患者提供新的用药选择，满足未被满足的临床需求。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300028857.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0196","BK0188","BK0183","BK0187","002294","BK0239"],"gpt_icon":0},{"id":"2586723913","title":"11月26日信立泰涨5.69%，中欧医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2586723913","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586723913?lang=zh_cn&edition=full","pubTime":"2025-11-26 15:35","pubTimestamp":1764142524,"startTime":"0","endTime":"0","summary":"证券之星消息，11月26日信立泰涨5.69%，收盘报62.46元，换手率0.72%，成交量8.0万手，成交额4.96亿元。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共80家，其中持有数量最多的公募基金为中欧基金的中欧医疗健康混合A。葛兰在任的基金产品包括:中欧明睿新起点混合，管理时间为2018年7月12日至今，期间收益率为63.69%；中欧医疗创新股票A，管理时间为2019年2月28日至今，期间收益率为56.94%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112600017691.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0183","BK0196","002294","BK0028","159760","BK0187"],"gpt_icon":0},{"id":"2585149907","title":"信立泰（002294）披露SAL0139获得临床试验批准通知书，11月21日股价下跌1.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585149907","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585149907?lang=zh_cn&edition=full","pubTime":"2025-11-21 22:30","pubTimestamp":1763735446,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘，信立泰报收于60.1元，较前一交易日下跌1.59%，最新总市值为670亿元。公司近日发布公告称，深圳信立泰药业股份有限公司近日收到国家药品监督管理局核准签发的《临床试验批准通知书》，同意公司自主研发的创新小分子药物SAL0139片开展治疗高脂血症的临床试验。若研发成功并获批上市，将有望为高脂血症患者提供新的用药选择，满足未被满足的临床需求，并丰富公司慢病领域的产品管线。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112100040286.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0183","002294","BK0028","BK0239","BK0187","BK0196"],"gpt_icon":0},{"id":"2585190253","title":"信立泰(002294.SZ)：创新小分子药物SAL0139获批开展治疗高脂血症临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2585190253","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585190253?lang=zh_cn&edition=full","pubTime":"2025-11-21 16:03","pubTimestamp":1763712187,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信立泰(002294.SZ)发布公告，近日，公司收到国家药品监督管理局核准签发的《临床试验批准通知书》，同意公司自主研发的创新小分子药物SAL0139片(项目代码：SAL0139)开展治疗高脂血症的临床试验。高脂血症是一种隐匿性强、危害广泛的代谢性疾病，长期未控制可引发多系统并发症，低密度脂蛋白胆固醇(LDL-C)相关的高胆固醇积累是导致心脑血管疾病的关键风险因素。临床前研究显示，SAL0139具有降低LDL-C的潜力，若能研发成功并获批上市，将有望为更多患者提供新的用药选择，提高患者依从性，满足未被满足的临床需求，并进一步丰富公司慢病领域的创新产品管线。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1372044.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"信立泰(002294.SZ)：创新小分子药物SAL0139获批开展治疗高脂血症临床试验","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0187","BK0239","BK0188","002294","BK0028","BK0183","BK0196"],"gpt_icon":0},{"id":"2583502716","title":"信立泰（002294）披露将参加深圳辖区上市公司投资者网上集体接待日活动，11月14日股价下跌0.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583502716","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583502716?lang=zh_cn&edition=full","pubTime":"2025-11-14 22:48","pubTimestamp":1763131699,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，信立泰报收于61.98元，较前一交易日下跌0.45%，最新总市值为690.96亿元。该股当日开盘61.99元，最高63.5元，最低61.05元，成交额达3.76亿元，换手率为0.54%。公司近日发布公告称，深圳信立泰药业股份有限公司将参加2025年度深圳辖区上市公司投资者网上集体接待日活动。公司管理层将就公司业绩、治理、发展战略、经营状况及可持续发展等问题与投资者在线交流。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400042132.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0183","BK0196","BK0028","BK0187","002294"],"gpt_icon":0},{"id":"2583552388","title":"11月13日信立泰涨5.40%，中欧医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2583552388","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583552388?lang=zh_cn&edition=full","pubTime":"2025-11-13 16:31","pubTimestamp":1763022717,"startTime":"0","endTime":"0","summary":"证券之星消息，11月13日信立泰涨5.40%，收盘报62.26元，换手率0.68%，成交量7.58万手，成交额4.68亿元。重仓信立泰的前十大公募基金请见下表：该股最近90天内共有10家机构给出评级，买入评级8家，增持评级2家；过去90天内机构目标均价为45.91。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共80家，其中持有数量最多的公募基金为中欧基金的中欧医疗健康混合A。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300027706.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0188","159760","BK0239","BK0028","BK0187","BK0196","002294"],"gpt_icon":0},{"id":"2582887037","title":"信立泰（002294）披露股东减持股份预披露公告，11月10日股价上涨2.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582887037","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582887037?lang=zh_cn&edition=full","pubTime":"2025-11-10 22:32","pubTimestamp":1762785126,"startTime":"0","endTime":"0","summary":"公司近日发布公告称，深圳市润复投资发展有限公司持有深圳信立泰药业股份有限公司股份15,465,952股，占公司总股本1.39%。其计划在本公告披露之日起15个交易日后的3个月内，通过集中竞价和/或大宗交易方式减持不超过80万股，占公司总股本0.07%。本次减持原因为股东蔡俊峰个人资金需求，股份来源为首发前股份及权益分派送转股份。本次减持不会导致公司控制权变化，不影响公司治理结构和持续经营能力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20251110/31782872.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0183","BK0188","BK0239","BK0028","BK0187","BK0196","002294"],"gpt_icon":0},{"id":"2582822140","title":"信立泰最新公告：股东润复拟减持不超0.07%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2582822140","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582822140?lang=zh_cn&edition=full","pubTime":"2025-11-10 18:31","pubTimestamp":1762770705,"startTime":"0","endTime":"0","summary":"信立泰(002294.SZ)公告称，股东深圳市润复投资发展有限公司计划减持不超过80万股（即80.00万股），占公司总股本比例0.07%，减持方式为集中竞价交易和/或大宗交易，减持原因为润复股东蔡俊峰的个人资金需求，减持期间为本公告披露之日起15个交易日后的3个月内。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111000027152.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0188","BK0239","BK0028","BK0187","BK0196","002294"],"gpt_icon":0},{"id":"2579915475","title":"信立泰（002294）2025年三季报简析：营收净利润同比双双增长，应收账款上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2579915475","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579915475?lang=zh_cn&edition=full","pubTime":"2025-10-29 06:28","pubTimestamp":1761690519,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期信立泰发布2025年三季报。截至本报告期末，公司营业总收入32.41亿元，同比上升8.01%，归母净利润5.81亿元，同比上升13.93%。按单季度数据看，第三季度营业总收入11.1亿元，同比上升15.85%，第三季度归母净利润2.16亿元，同比上升30.19%。本报告期信立泰应收账款上升，应收账款同比增幅达41.08%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900009348.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002294"],"gpt_icon":0},{"id":"2578936009","title":"信立泰(002294)9月30日股东户数2.52万户，较上期增加4.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578936009","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578936009?lang=zh_cn&edition=full","pubTime":"2025-10-28 17:32","pubTimestamp":1761643934,"startTime":"0","endTime":"0","summary":"证券之星消息，近日信立泰披露，截至2025年9月30日公司股东户数为2.52万户，较6月30日增加1169.0户，增幅为4.87%。在化学制药行业个股中，信立泰股东户数低于行业平均水平，截至9月30日，化学制药行业平均股东户数为3.38万户。从股价来看，2025年6月30日至2025年9月30日，信立泰区间涨幅为27.51%，在此期间股东户数增加1169.0户，增幅为4.87%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800031714.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0183","BK0239","BK0028","BK0188","002294","BK0187"],"gpt_icon":0},{"id":"2578280116","title":"信立泰最新公告：前三季净利润5.81亿元同比增长13.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578280116","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578280116?lang=zh_cn&edition=full","pubTime":"2025-10-27 23:11","pubTimestamp":1761577877,"startTime":"0","endTime":"0","summary":"信立泰发布2025年第三季度报告，第三季度实现营业收入11.10亿元，同比增长15.85%；归属于上市公司股东的净利润为2.16亿元，同比增长30.19%。前三季度实现营业收入32.41亿元，同比增长8.00%；归属于上市公司股东的净利润为5.81亿元，同比增长13.93%。业绩增长主要得益于新产品营收增速提升，已成为驱动公司发展的核心动力。同时，公司加大研发投入，推进数字化慢病管理，并完成对巴特勒公司的收购，进一步增强业务协同与盈利能力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102700037295.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002294"],"gpt_icon":0},{"id":"2576453863","title":"信立泰（002294）披露JK06境外临床试验进展，10月20日股价下跌1.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2576453863","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576453863?lang=zh_cn&edition=full","pubTime":"2025-10-20 22:42","pubTimestamp":1760971334,"startTime":"0","endTime":"0","summary":"截至2025年10月20日收盘，信立泰报收于55.73元，较前一交易日下跌1.71%，最新总市值为621.29亿元。近日，深圳信立泰药业股份有限公司发布关于JK06境外临床试验进展的公告。公告显示，公司子公司美国Salubris Biotherapeutics, Inc.在2025年欧洲肿瘤内科学会年会上展示了JK06 I/II期临床试验的部分剂量递增数据。数据显示，JK06在不可切除的局部晚期或转移性肿瘤患者中表现出良好的安全性和疗效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102000032604.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0183","BK0187","BK0188","BK0028","002294","BK0239"],"gpt_icon":0},{"id":"2575207914","title":"信立泰(002294.SZ)SAL0137药品临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2575207914","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575207914?lang=zh_cn&edition=full","pubTime":"2025-10-15 17:31","pubTimestamp":1760520680,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信立泰(002294.SZ)公告，公司收到国家药品监督管理局核准签发的受理通知书，公司自主研发的创新小分子药物SAL0137片(项目代码：SAL0137)临床试验申请获得受理。SAL0137是公司研发的具有自主知识产权的口服小分子药物，公司本次提交的申请为SAL0137用于治疗脂蛋白(a)增高的临床试验申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1355388.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0187","BK0239","BK0188","BK0183","BK0196","002294"],"gpt_icon":0},{"id":"2571927381","title":"信立泰最新公告：JK07、JK06境外临床试验取得阶段性进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2571927381","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2571927381?lang=zh_cn&edition=full","pubTime":"2025-09-29 18:11","pubTimestamp":1759140670,"startTime":"0","endTime":"0","summary":"信立泰公告称，公司子公司Salubris Biotherapeutics, Inc.自主研发的创新生物药JK07、JK06取得进展。JK07的II期临床试验旨在评估其在心衰患者中的安全性和有效性。此外，JK07在左心疾病所致的肺动脉高压的临床方案已获FDA批准，启动IIa期临床研究。JK06为5T4抗体药物偶联物，正在欧洲开展I期临床试验，预计年内开展剂量拓展阶段研究，初步数据计划于2025年10月在欧洲肿瘤内科学会年会展示。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092900025469.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0239","BK0187","002294","BK0188","BK0183","BK0028"],"gpt_icon":0},{"id":"2571866203","title":"信立泰(002294.SZ)：SAL0140药品临床试验申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2571866203","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2571866203?lang=zh_cn&edition=full","pubTime":"2025-09-29 17:30","pubTimestamp":1759138233,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信立泰 发布公告，近日，公司收到国家药品监督管理局核准签发的受理通知书，公司自主研发的创新小分子药物SAL0140片新适应症临床试验申请获得受理。目前，SAL0140即将开展II期临床。与原发性高血压患者相比，原醛症患者靶器官损害更严重，心血管疾病发生风险更高。SAL0140若能研发成功并获批上市，将有望为更多细分领域的患者有针对性地提供新的用药选择，满足未被满足的临床需求，并进一步丰富公司慢病领域的创新产品管线。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1350647.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0239","002294","BK0028","BK0196","BK0183","BK0187"],"gpt_icon":0},{"id":"2569451798","title":"9月23日信立泰涨5.55%，中欧医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2569451798","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569451798?lang=zh_cn&edition=full","pubTime":"2025-09-23 16:30","pubTimestamp":1758616248,"startTime":"0","endTime":"0","summary":"证券之星消息，9月23日信立泰涨5.55%，收盘报54.76元，换手率0.95%，成交量10.64万手，成交额5.62亿元。重仓信立泰的前十大公募基金请见下表：该股最近90天内共有8家机构给出评级，买入评级6家，增持评级2家；过去90天内机构目标均价为45.91。根据2025基金半年报公募基金重仓股数据，重仓该股的公募基金共74家，其中持有数量最多的公募基金为中欧基金的中欧医疗健康混合A。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092300025846.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0183","BK0196","BK0187","159760","BK0028","002294"],"gpt_icon":0},{"id":"2567199258","title":"研报掘金丨天风证券：维持信立泰“买入”评级，多条管线有望迎来收获期","url":"https://stock-news.laohu8.com/highlight/detail?id=2567199258","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567199258?lang=zh_cn&edition=full","pubTime":"2025-09-15 15:40","pubTimestamp":1757922027,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["III","BK0183","BK0188","601162","BK0239","BK0187","BK4134","BK0028","LU1223082196.USD","CDE","LU1223082519.USD","BK0196","BK4017","159839","LU1223083913.SGD","BK0276","002294"],"gpt_icon":0},{"id":"2565557340","title":"信立泰(002294.SZ)：SAL0139药品临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2565557340","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565557340?lang=zh_cn&edition=full","pubTime":"2025-09-05 19:21","pubTimestamp":1757071305,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信立泰(002294.SZ)公告，公司收到国家药品监督管理局核准签发的受理通知书，公司自主研发的创新小分子药物SAL0139片(项目代码：SAL0139)临床试验申请获得受理。公告显示，SAL0139是公司具有自主知识产权的小分子药物，公司本次提交的申请为SAL0139用于治疗高血脂症的临床试验申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1342131.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"信立泰(002294.SZ)：SAL0139药品临床试验申请获受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0239","BK0183","BK0196","002294","BK0028","BK0187"],"gpt_icon":0},{"id":"2565557542","title":"信立泰最新公告：恩那罗®新增适应症获批 用于治疗透析慢性肾脏病患者贫血","url":"https://stock-news.laohu8.com/highlight/detail?id=2565557542","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565557542?lang=zh_cn&edition=full","pubTime":"2025-09-05 19:20","pubTimestamp":1757071234,"startTime":"0","endTime":"0","summary":"信立泰公告称，公司收到国家药品监督管理局核准签发的恩那度司他片（恩那罗）药品注册证书，新增适应症为治疗透析慢性肾脏病患者的贫血。恩那罗是新一代缺氧诱导因子脯氨酰羟化酶抑制剂药物，已获批用于非透析的成人CKD患者贫血治疗，并纳入国家医保目录。新适应症的获批将为更多肾性贫血患者带来新的用药选择。新适应症的获批对公司业绩和长远发展有积极影响，但具体销售情况受市场环境等因素影响，存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090500034216.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0187","002294","BK0028","BK0196","BK0239","BK0183"],"gpt_icon":0},{"id":"2562086329","title":"信立泰(002294.SZ)：自研创新小分子药物SAL0140片临床试验申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2562086329","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562086329?lang=zh_cn&edition=full","pubTime":"2025-08-28 16:10","pubTimestamp":1756368616,"startTime":"0","endTime":"0","summary":"智通财经APP讯， 信立泰(002294.SZ)发布公告，近日，公司收到国家药品监督管理局核准签发的受理通知书，公司自主研发的创新小分子药物SAL0140片(项目代码：SAL0140)临床试验申请获得受理。SAL0140 是公司具有自主知识产权的醛固酮合酶抑制剂，拟开发适应症包括未控制高血压(包括难治性高血压)、慢性肾脏病(CKD)等。目前，SAL0140 (未控制高血压)正处于I期临床阶段。SAL0140 若能研发成功并获批上市，将有望为更多细分领域的高血压患者及CKD患者有针对性地提供新的用药选择，满足未被满足的临床需求，并进一步丰富公司慢病领域的创新产品管线。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1337158.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"信立泰(002294.SZ)：自研创新小分子药物SAL0140片临床试验申请获得受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002294","BK0183","BK0188","BK0028","BK0196","BK0239","BK0187"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765052695295,"stockEarnings":[{"period":"1week","weight":-0.0218},{"period":"1month","weight":0.0478},{"period":"3month","weight":0.037},{"period":"6month","weight":0.2864},{"period":"1year","weight":0.8306},{"period":"ytd","weight":0.9815}],"compareEarnings":[{"period":"1week","weight":0.0037},{"period":"1month","weight":-0.0167},{"period":"3month","weight":0.0237},{"period":"6month","weight":0.1529},{"period":"1year","weight":0.1585},{"period":"ytd","weight":0.1644}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"深圳信立泰药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"25188人(较上一季度增加4.87%)","perCapita":"44249股","listingDate":"2009-09-10","address":"广东省深圳市福田区福保街道福保社区红柳道2号289数字半岛4层A区","registeredCapital":"111481万元","survey":" 深圳信立泰药业股份有限公司的主营业务是药品、医疗器械产品的研发、生产、销售，以及专利授权许可。公司的主要产品是心血管类药物及医疗器械、头孢类抗生素及原料、骨科药物。","listedPrice":41.98},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信立泰(002294)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信立泰(002294)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信立泰,002294,信立泰股票,信立泰股票老虎,信立泰股票老虎国际,信立泰行情,信立泰股票行情,信立泰股价,信立泰股市,信立泰股票价格,信立泰股票交易,信立泰股票购买,信立泰股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信立泰(002294)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信立泰(002294)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}